Biocon Ltd - BIOCON Share Price

Sector: Pharmaceuticals | ISIN: INE376G01013
₹ 264.35 (-0.99%) icon22 Sep, 2023, 3:59:09 PM
Open
₹ 267.00
Prev. Close
₹ 267.00
Turnover(lac)
₹ 9,555.82
Day's High
₹ 269.25
Day's Low
₹ 261.30
52 Wk High
₹ 299.15
52 Wk Low
₹ 191.55
Book Value
₹ 91.30
Face Value
₹ 5.00
Mkt. Cap (Cr.)
₹ 31,737.86
P/E
296.57
EPS
0.89
Div. Yield
0.57

Biocon Ltd Stock View

info icon
Edit Image
BUY
Target | 09 Sep, 2023 289.5 (9.51%)

Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics an... Read More

Biocon Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 9/22/2023 3:59:09 PM

    ₹ 264.35 -2.65 -0.99
  • Open
  • ₹ 267
  • Prev. Close
  • ₹ 267
  • Turnover(Lac.)
  • ₹ 9,556
  • Day's High
  • ₹ 269.25
  • Day's Low
  • ₹ 261.3
  • 52 Week's High
  • ₹ 299.15
  • 52 Week's Low
  • ₹ 191.55
  • Book Value
  • ₹ 91.3
  • Face Value
  • ₹ 5
  • Mkt Cap (₹ Cr.)
  • 31,737.86
  • P/E
  • 296.57
  • EPS
  • 0.89
  • Divi. Yield
  • 0.57

Biocon Ltd Corporate Actions

23 May , 2023

12:00 AM

AGM

Announcement date: 23 May , 2023

View Details

21 Jul , 2023

12:00 AM

21 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 May , 2023

12:00 AM

Dividend

Dividend amount: 1.5
Announcement date: 23 May , 2023

View Details

20 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Apr , 2023

12:00 AM

23 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

06 Jan , 2023

12:00 AM

20 Oct , 2022

12:00 AM

20 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

Biocon Ltd News and Update

Image not found
  • 1 day ago |
  • 8:26 PM

Nirma Ltd. will conduct a required open offer to all public shareholders of GLS in accordance with SEBI regulations.

Article Image
Image not found
Image not found
  • IIFL News Service |
  • 21 September, 2023 |
  • 8:24 PM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Biocon Ltd SHAREHOLDING SNAPSHOT
24 September , 2023 | 08:02 AM

PROMOTER - TOTAL60.64%

Indian: 39.66%

Foreign: 20.9801%

NON-PROMOTER - TOTAL 38.87%

Institutions: 22.11%

Non-Institutions: 16.76%

CUSTODIES - 0.49%

Custodies: 0.49%

See More Details
ad IconAd Image

Biocon Ltd FINANCIALS

Biocon Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Biocon Ltd

  • Kiran Mazumdar Shaw
  • Chairperson
  • Ravi Mazumdar
  • Director
  • Vijay Kumar Kuchroo
  • Independent Director
  • M Damodaran
  • Independent Director
  • Bobby Parikh
  • Independent Director
  • Mayank Verma
  • Company Sec. & Compli. Officer
  • SIDDHARTH MITTAL
  • Managing Director & CEO
  • Eric Vivek Mazumdar
  • Director
  • Naina Lal Kidwai
  • Independent Director
  • Peter John Bains
  • Independent Director

Summary

Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. The Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International. Also in the same year, the company had received US funding for proprietary technologies. After a year, in 1990, Biocon had scaled up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level. Biocons R&D and manufacturing facilities received ISO 9001 certification from RWTUV, Germany during the period of 1993. In the year 1994, the company had established the Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector. The commercial success of Biocons proprietary fermentation plant leads to a 3-fold expansion during the year 1996 and also in the same year, the company had leveraged its technology platform to enter biopharmaceuticals and statins. Biocon had spearheads initiatives in human healthcare in the year 1997 through a dedicated manufacturing... Read More


Reports by Biocon Ltd


Reports by Biocon Ltd

Company FAQ

No Record Found